Cross-priming, a process in which DCs activate CD8+ T cells by cross-presenting exogenous antigens, is critical for generating anti-tumor CD8+ killer T cell immunity (Zamora et al. 2018; Farhood et al. 2019). The gene discussed is CD8A; the disease is neoplasm.